Helicobacter

Helicobacter

幽门螺杆菌

  • 2区 中科院分区
  • Q1 JCR分区

期刊简介

《Helicobacter》是由Wiley-Blackwell Publishing Ltd出版社于1996年创办的英文国际期刊(ISSN: 1083-4389,E-ISSN: 1523-5378),该期刊长期致力于胃肠肝病学领域的创新研究,主要研究方向为医学-微生物学。作为SCI、SCIE收录期刊(JCR分区 Q1,中科院 2区),本刊采用OA未开放获取模式(OA占比0.0969...%),以发表胃肠肝病学领域等方向的原创性研究为核心(研究类文章占比83.12%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在77篇,确保学术质量与前沿性。成果覆盖Web of ScienceWeb of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Helicobacter审稿周期约为约2月。该刊近年未被列入国际预警名单,年发文量约77篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCI、SCIE 期刊收录
  • 77 发文量

中科院分区

《新锐期刊分区表》(2026年3月发布)

Top期刊 综述期刊 大类学科 小类学科
医学
2区
GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学 MICROBIOLOGY 微生物学
2区 2区

期刊分区表(2025年3月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
2区
MICROBIOLOGY 微生物学 GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学
2区 3区

期刊分区表(2023年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
2区
MICROBIOLOGY 微生物学 GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学
2区 3区

期刊分区表(2022年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
2区
MICROBIOLOGY 微生物学 GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学
2区 3区

期刊分区表(2021年12月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
2区
GASTROENTEROLOGY & HEPATOLOGY 胃肠肝病学 MICROBIOLOGY 微生物学
3区 3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 38 / 153

75.5

学科:MICROBIOLOGY SCIE Q2 51 / 167

69.8

学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q2 41 / 153

73.53

学科:MICROBIOLOGY SCIE Q2 59 / 167

64.97

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 30 / 148

80.1

学科:MICROBIOLOGY SCIE Q2 45 / 163

72.7

学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 35 / 148

76.69

学科:MICROBIOLOGY SCIE Q2 52 / 163

68.4

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q1 29 / 143

80.1

学科:MICROBIOLOGY SCIE Q2 44 / 161

73

学科:GASTROENTEROLOGY & HEPATOLOGY SCIE Q2 36 / 143

75.17

学科:MICROBIOLOGY SCIE Q2 54 / 161

66.77

CiteScore(2026年6月最新版)

CiteScore SJR SNIP CiteScore 排名
CiteScore:8 SJR:1.079 SNIP:1.101
学科类别 分区 排名 百分位
大类:Medicine 小类:Gastroenterology Q1 18 / 176

90%

大类:Medicine 小类:Infectious Diseases Q1 46 / 361

87%

期刊发文

  • Hope Hp-GC Project-Program Implementation for Primary and Secondary Prevention of Gastric Cancer in Latin Americ

    Author: Uribe, Javier; Portillo-Mino, Jose Dario; Latorre, Gonzalo; Reyes-Placencia, Diego; Pizarro, Mauricio; Vargas, Jose Ignacio; Espino, Alberto; Jure, Camila; Pizarro, Margarita; Bofill, Gabriela; Silva, Felipe; Palacios, Nilton; Diaz-Garrido, Natalia; Huidobro, Laura; Araya, Raul; Ledesma, Sergio; Otero, William; Otero, Lina; Remes-Troche, Jose M.; Campos, Christian; Largacha, Monserrate; Varas, Oscar; Cabrera, Dacio; Piscoya, Alejandro; Ramirez, Juan; Laudanno, Oscar; Esteves, Sebastian; Cifuentes, Sandra; Garcia, Eduardo; Maria-Guzman, Ana; Morgan, Douglas; Espinoza, Manuel; Shah, Shailja C.; Park, Jin Young; Camargo, M. Constanza; Riquelme, Arnoldo

    Journal: HELICOBACTER. 2026; Vol. 31, Issue 2, pp. -. DOI: 10.1111/hel.70109

  • Vonoprazan Versus Tegoprazan-Amoxicillin Dual Therapy for Treatment-Naïve Patients With Helicobacter pylori Infection: A Prospective, Multicenter, Open-Label, Randomized Controlled Stud

    Author: Zhou, Ya-Ni; Song, Ji-Chun; Wang, Qing-Hua; Feng, Huang; Lin, Ya; Li, De-Min; Wang, Ge; Huang, Xiao-Wei; Liu, Jing-Mei; Shen, Yan; Zhou, Xiang; Xue, Hui-Ting; Liu, Yan; Li, Pei-Yuan

    Journal: HELICOBACTER. 2026; Vol. 31, Issue 2, pp. -. DOI: 10.1111/hel.70124

  • Changes of Helicobacter pylori Infection Status and Risk of Precancerous Lesions: A Prospective Cohort Study in Chinese Populatio

    Author: Xing, Xufei; Zhao, Renjia; Cui, Zixuan; Xu, Qiaoyi; Yuan, Ziyu; Xu, Kelin; Zhang, Tiejun; Liu, Zhenqiu; Jiang, Yanfeng; Lu, Ming; Ye, Weimin; Suo, Chen; Chen, Xingdong

    Journal: HELICOBACTER. 2026; Vol. 31, Issue 2, pp. -. DOI: 10.1111/hel.70114

  • Efficacy and Safety of Vonoprazan-Based Dual, Triple, and Quadruple Therapies for Helicobacter pylori Eradication: A Randomized Controlled Tria

    Author: Zhang, Jin-Yan; Li, Ji; Huang, Wei-Feng; Lei, Xiao-Yi; Huang, Yu-Lin; Xu, Gui-Hua; Xu, Dong

    Journal: HELICOBACTER. 2026; Vol. 31, Issue 2, pp. -. DOI: 10.1111/hel.70112

  • Exosome-Based Detection of Helicobacter pylori Infection and Clarithromycin Resistance in Childre

    Author: Song, Minghui; Zeng, Jingqing; Yao, Zhanyong; Xu, Chundi; Huang, Yiqiu; Xiao, Yuan; Yu, Yi; Li, Jia; Xu, Xu; Shi, Chenchen; Wu, Qiuchen; Tao, Yonglin; Tang, Xing; Ge, Gloria; Gao, Shenshen; Deng, Zhaohui; Wang, Xinqiong

    Journal: HELICOBACTER. 2026; Vol. 31, Issue 2, pp. -. DOI: 10.1111/hel.70113

  • Efficacy and Safety of Keverprazan-Amoxicillin Dual Regimen in Initial Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Tria

    Author: Wei, Shanshan; Huang, Zhihao; Xiong, Huizhen; Wu, Ji; Mei, Dihua; Zhao, Jing; Liu, Wei; Liu, Qingyun; Lin, Yu; Liu, Fang; Peng, Xiang; Chen, Honglei

    Journal: HELICOBACTER. 2026; Vol. 31, Issue 1, pp. -. DOI: 10.1111/hel.70100

  • The Systemic Impact of Helicobacter pylori Infection on the Microbiome of Whole Digestive Tract Based on Mucosal, Gastric Juice, and Fecal Specimen

    Author: Wang, Yuxin; Zhou, Kai; Zhang, Yuexi; Li, Cailing; Zhang, Yuxin; Ren, Xinlu; Mi, Changmin; Ma, Lingling; Duan, Yuqi; Liu, Mengqi; Ping, Guangjie; Tian, Xueli; Song, Zhiqiang

    Journal: HELICOBACTER. 2025; Vol. 30, Issue 3, pp. -. DOI: 10.1111/hel.70047

  • Reply: Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Tria

    Author: Ren, Xinlu; Song, Zhiqiang

    Journal: HELICOBACTER. 2025; Vol. 30, Issue 3, pp. -. DOI: 10.1111/hel.70043